KLRANasdaqPharmaceutical PreparationsFiscal year ends December 31
Kailera Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 12, 2026
$11.43+0.18 (+1.60%)
Close on Oct 19, 2026
- Market cap
- $1.17B
- P/E (TTM)
- –
- Dividend yield
- –
SEC filings
5 of Kailera Therapeutics's most recent filings on SEC EDGAR
| Document | Form | Period | Filed | Source |
|---|---|---|---|---|
| Quarterly report | 10-Q | Jun 30, 2026 | Aug 12, 2026 | SEC EDGAR |
| Current report | 8-K | Aug 12, 2026 | Aug 12, 2026 | SEC EDGAR |
| Quarterly report | 10-Q | Mar 31, 2026 | May 26, 2026 | SEC EDGAR |
| Current report | 8-K | May 26, 2026 | May 26, 2026 | SEC EDGAR |
| Current report | 8-K | Apr 20, 2026 | Apr 20, 2026 | SEC EDGAR |